Nav1.2 blockers(Sodium channel protein type II alpha subunit blockers), PI4K activators(Phosphatidylinositol 4-kinase activators), SIRT1 stimulants(NAD-dependent deacetylase sirtuin 1 stimulants)

+ [2]

Therapeutic Areas

NeoplasmsCardiovascular DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Reperfusion InjuryHypertensionBreast Cancer

Inactive Indication

Hepatocellular Carcinoma

Originator Organization

Beijing Xinliheng Medical Technology Development Co., Ltd.

Active Organization

Chungnam National University College of Medicine

Daejeon UniversityYonsei University College of Medicine

+ [2]

Inactive Organization

Jilin University Zhengyuan Information Technologies Co., Ltd.

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC42H72O13

InChIKeyRWXIFXNRCLMQCD-JBVRGBGGSA-N

CAS Registry14197-60-5

Clinical Trials associated with 20(S)-Ginsenoside-Rg3

NCT04523467

/ Unknown statusNot ApplicableIIT

A Multicentre Randomized Controlled Study of Anti-angiogenic Targeted Drugs Combined With Ginsenoside Rg3 to Improve the Efficacy of Transcatheter Arterial Chemoembolization (TACE) in the Treatment of Unresectable Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with the anti-angiogenic targeted drugs and ginsenoside Rg3 versus TACE alone in patients with unresectable Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC), who has normal liver function and no extrahepatic metastasis.

Start Date01 Dec 2020

Sponsor / Collaborator

Shanghai Eastern Hepatobiliary Surgery Hospital

100 Clinical Results associated with 20(S)-Ginsenoside-Rg3

100 Translational Medicine associated with 20(S)-Ginsenoside-Rg3

100 Patents (Medical) associated with 20(S)-Ginsenoside-Rg3

2,465

Literatures (Medical) associated with 20(S)-Ginsenoside-Rg3

31 Dec 2025·Drug Delivery

Synergistic effect of pH-sensitive PEGylated RG3-chitosan prodrug nanoparticles encapsulated celastrol on pancreatic cancer

Article

Author: Wu, Xiangxiang ; Zhang, Zheng ; Zhao, Lingzhou ; Su, Mengjiao ; Li, Xiaofang ; Wang, Jiaxing ; Zeng, Huahui ; Zhao, Junwei

Celastrol (Cel) is a potential anticancer therapeutic candidate, but its limited practical applicability is due to its low solubility, poor tumor selectivity, and cytotoxicity. Clinically, ginsenoside Rg3 (RG3) is typically combined with chemotherapy to enhance antitumor effects and reduce side effects. Herein, we developed novel pH-sensitive prodrug nanoparticles (NPs) containing RG3 and Cel for the synergistic treatment of pancreatic cancer (PC). Amphiphilic prodrug, a PEGylated chitosan oligosaccharide coupled with RG3 via Schiff base bond, was self-assembled with hydrophobic Cel into NPs with drug loadings of 2.12% (Cel) and 1.63% (RG3). NPs exhibited a suitable particle size of 124.01 nm, zeta potential of -39.89 mV and good physical stability. In addition, NPs also showed a controlled drug release when the Schiff base bonds were hydrolyzed in the acidic environment. In Pan02 tumor-bearing mice, NPs exhibited a high accumulation in tumor tissues and prolonged blood circulation time. Furthermore, NPs could more effectively inhibit tumor growth and reduce systemic toxicity, compared with the free Cel, RG3, prodrug, and Cel + RG3. The results indicated that the NPs could provide a safe and promising nanoplatform for PC therapy.

30 Mar 2025·Journal of the Science of Food and Agriculture

Metabolomics‐based analysis of nitric oxide regulation of ginseng herb quality

Article

Author: Meng, Zhaoping ; Liu, Wenfei ; Zhang, Wei ; Liu, Xiubo ; Meng, Xiangcai ; Wang, Liyang ; Song, Xiaowen ; Yao, Yao ; Yu, Pengcheng

AbstractBACKGROUNDGinsenosides, the primary active ingredients in Panax ginseng, are secondary metabolites. However, their content varies significantly across batches due to differences in environmental conditions and production methods. Ecological stress can increase the levels of reactive oxygen species (ROS) in plants, and ROS can enhance secondary metabolism. Nitric oxide (NO) can promote the production of O2·‐ and H2O2. This study utilized physiological and non‐targeted metabolomics to investigate how NO regulates ginseng quality and how P. ginseng adapts to adversity.RESULTSSodium nitroprusside (SNP, an NO donor) at 0.5 mmol·L−1 significantly increased ROS levels, with O2·‐ increasing by 64.3% (P < 0.01) and H2O2 by 79.2% (P < 0.01). Nitric oxide influenced P. ginseng metabolism, with 24 metabolites showing significant differences. Rotenone, lactic acid, and gluconic acid, which are involved in ROS metabolism, increased significantly, whereas tyrosine decreased. Metabolites involved in secondary metabolic pathways, including campesterol, ginsenosides Rh1, Rb1, Rc, Rd, Rg3, phenylalanine, and tryptophan, increased markedly, whereas 2,3‐oxidosqualene, glucose 1‐phosphate, ferulic acid, and pyrogallol decreased. Isocitric acid, succinic acid, and 3‐isopropylmalic acid, associated with respiratory metabolism, showed significant increases, but pyruvic acid decreased. Finally, 18:0 Lyso PC and 9‐hydroxy‐10E,12Z‐octadecadienoic acid, linked to cell membrane protection, increased significantly, and mannose and raffinose decreased.CONCLUSIONSodium nitroprusside enhances the physiological resilience of P. ginseng under stress and improves its quality. © 2024 Society of Chemical Industry.

01 Mar 2025·Journal of Pharmaceutical and Biomedical Analysis

Metabolite profiling of Shenhua compound in rats and pharmacokinetics study of four bioactive compounds with liquid chromatography combined with electrospray ionization tandem mass spectrometry

Article

Author: Han, Han ; Tang, Jie ; Gu, Yun ; Chen, Ze-Xuan ; Song, Pei-Rong ; Zou, Lu ; Li, Ling ; Lim, Xue-Yee ; Zhang, Tong ; Shi, Meng-Ge

Shenhua compound, composed of ginseng, hawthorn and sophora flower, has been shown to improve hyperlipidemia. However, the main ingredients, their metabolic pathways in vivo, and pharmacokinetic characteristics. In this study, ultra-high-performance liquid chromatography coupled with electrospray ionization quadruple time-of-flight mass spectrometry (UHPLC-Q-TOF) was used to qualitatively analyze the main ingredients in ethanol extract of Shenhua compound and to investigate the metabolites in serum, bile, feces, and urine of rats following oral administration. The pharmacokinetics of ginsenoside Rg₁, ginsenoside Re, ginsenoside Ro and rutin in rats were analyzed using triple-quadrupole liquid chromatography combined with electrospray ionization mass spectrometry (QQQ-LC/MS). The results indicated that 48 compounds were present in Shenhua compound, including saponins, flavonoids and organic acids. Metabolites were comprehensively analyzed after oral administration of Shenhua compound, and 24 prototype ingredients and 92 metabolite ingredients were identified or characterized. By analyzing the pharmacokinetic parameters of ginsenoside Rg₁, ginsenoside Re, ginsenoside Ro and rutin from 0 to 72 h after oral administration of various dose of Shenhua compound, it was observed that the concentration of ginsenosides in blood remained below 2 ng∙mL¹, but the metabolic excretion time was prolonged. Meanwhile, the blood concentration of rutin was significantly higher than ginsenosides and showed a double absorption peak. In conclusion, this study provides valuable insights into compound ingredients metabolism regularities in vivo and pharmacokinetics after oral administration of Shenhua compound.

100 Deals associated with 20(S)-Ginsenoside-Rg3

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Reperfusion Injury	Preclinical	South Korea	Chungnam National University College of Medicine	01 Apr 2024
Reperfusion Injury	Preclinical	South Korea	Daejeon University	01 Apr 2024
Hypertension	Preclinical	South Korea	Chosun University Hospital	01 Jun 2023
Breast Cancer	Preclinical	South Korea	Yonsei University College of Medicine	15 Apr 2011
Breast Cancer	Preclinical	South Korea	Yonsei University	15 Apr 2011
Hepatocellular Carcinoma	Discovery	China	Jilin University Zhengyuan Information Technologies Co., Ltd.	01 Oct 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

20(S)-Ginsenoside-Rg3

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation